Apollon Wealth Management LLC grew its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 14.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,708 shares of the company’s stock after acquiring an additional 4,076 shares during the quarter. Apollon Wealth Management LLC owned 0.50% of VanEck Pharmaceutical ETF worth $2,822,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in PPH. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management increased its holdings in VanEck Pharmaceutical ETF by 117.4% in the 4th quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 200,000 shares of the company’s stock worth $17,256,000 after purchasing an additional 108,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of VanEck Pharmaceutical ETF by 51.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 248,473 shares of the company’s stock worth $23,565,000 after purchasing an additional 84,273 shares during the last quarter. Adamsbrown Wealth Consultants LLC increased its stake in shares of VanEck Pharmaceutical ETF by 102.3% in the fourth quarter. Adamsbrown Wealth Consultants LLC now owns 149,631 shares of the company’s stock valued at $12,910,000 after buying an additional 75,659 shares during the period. Thrivent Financial for Lutherans raised its holdings in VanEck Pharmaceutical ETF by 33.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock valued at $22,322,000 after buying an additional 59,025 shares during the last quarter. Finally, Miller Investment Management LP boosted its position in VanEck Pharmaceutical ETF by 13.4% during the 3rd quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock worth $19,722,000 after buying an additional 24,446 shares during the period.
VanEck Pharmaceutical ETF Price Performance
PPH opened at $89.40 on Monday. The company’s 50 day moving average price is $87.76 and its two-hundred day moving average price is $91.72. The firm has a market capitalization of $557.86 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a fifty-two week low of $84.48 and a fifty-two week high of $99.51.
VanEck Pharmaceutical ETF Increases Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Financial Services Stocks Investing
- 3 Volatility ETFs to Help You Profit from Market Chaos
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- How is Compound Interest Calculated?
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.